Fri, Sep 19, 2014, 8:22 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • crossmebaby123 crossmebaby123 Dec 9, 2013 8:40 AM Flag

    PCYC management where is our news from ASH?????

    where the heck is it

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Key dates .Dec 9 Dec, 10 read,Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a phase 1b study. (Abstract 525)
      Oral session: CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials. Monday, December 9 at 3:15 pm CST in Ernest N. Morial Convention Center, 220-222

      Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852)
      Oral session: Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas. Tuesday, December 10 at 8:45 am CST in Ernest N. Morial Convention Center, La Nouvelle Ballroom AB The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) monotherapy demonstrates long-term safety and durability of response in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in an open-label extension study. (Abstract 4163)
      Poster session: CLL: Therapy, excluding Transplantation: Poster I. Monday, December 9 at 6:00-8:00 pm CST in Ernest N. Morial Convention Center, Hall E Less

      Sentiment: Strong Buy

    • Later today, this evening, and more tomorrow.

    • What is ASH?

123.52-1.45(-1.16%)Sep 19 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.